Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Unicycive Therapeutics (UNCY) has shared an update.
Unicycive Therapeutics, Inc. has announced significant success in their Oxylanthanum Carbonate (OLC) UNI-OLC-201 clinical trial, meeting both primary and secondary endpoints. This breakthrough was shared in a press release and during a corporate presentation, signaling potentially positive impacts for the company’s future and stirring interest among investors and market watchers.
See more data about UNCY stock on TipRanks’ Stock Analysis page.